Corcept Therapeutics | CORT - Assets


Corcept Therapeutics reported $888.7M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Aurora Cannabis CAD 601.09M 174.2M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
J&J USD 201.06B 167M Jun/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.24B 35.44M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026